Updated time: 2021-04-20 16:08:46
28A-1060221
TW I719315、US provisional pending
We demonstrate multiple cardiac glycosides like digoxin, digitoxin, ouabain, digitoxigenin, lanatoside C, proscillaridin A. bufalin, can eliminate undifferentiated ESCs within 24 hours. Cardiac glycosides spare the hPSC-derived mesenchymal stem cells, neuron, and hepatocytes. Most importantly, cardiac glycosides did not affect mesenchymal stem cells differentiation ability. Furthermore, in vivo mice experiments demonstrated that cardiac glycosides digoxin, lanatoside C prevented teratoma formation. This is the first study that describe the tumor prevention of cardiac glycosides in undifferentiated hPSCs, and the first FDA-approved drug (Digoxin and lanatoside C) that have cytotoxicity in undifferentiated hPSCs.
- The only FDA approved drug that can prevent the tumorigenicity of hPSCs.
- The cardiac glycosides is cheap.
- The cytotoxicity of cardiac glycosides in hPSCs is very effective, can eliminate the undifferentiated hPSCs within 24 hours.
- Cardiac glycosides do not affect the viability or function of the hPSC-derived cells
Regenerative medicine. In the tissue culture, use cardiac glycosides to remove left over undifferentiated cells to prevent teratoma. It can be applied to cell therapy that use hPSCs (include embryonic stem cells and induced pluripotent stem cells) derived cells.
Joyce Jean Lu, Yu-Tsen Lin
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

A method to eliminate oncogenic undifferentiated human pluripotent stem cells by cardiac glycosides